{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000604","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2025-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.041058+00:00","generated_at":"2026-05-23T18:10:26.737283+00:00","sec_items":["5.03","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"confidence":"high","headline":"Lipella increases designated Series C preferred shares from 1,050,000 to 1,260,000","bullets":["Filed Certificate of Amendment on April 8, 2025, increasing Series C Voting Convertible Preferred Stock designation from 1,050,000 to 1,260,000 shares.","Amendment modifies existing Certificate of Designation, potentially altering voting or conversion rights of current holders.","Change in authorized shares may indicate future financing or strategic moves by the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000604","json":"https://secwatch.observer/filing/0001753926-25-000604.json","markdown":"https://secwatch.observer/filing/0001753926-25-000604.md","text":"https://secwatch.observer/filing/0001753926-25-000604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000604/0001753926-25-000604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000604/g084766_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:10:26.737283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}